EP3432885A4 - Compositions et méthodes pour augmenter la durée de vie métabolique de dextrométhorphane et effets pharmacodynamiques associés - Google Patents

Compositions et méthodes pour augmenter la durée de vie métabolique de dextrométhorphane et effets pharmacodynamiques associés Download PDF

Info

Publication number
EP3432885A4
EP3432885A4 EP17771287.4A EP17771287A EP3432885A4 EP 3432885 A4 EP3432885 A4 EP 3432885A4 EP 17771287 A EP17771287 A EP 17771287A EP 3432885 A4 EP3432885 A4 EP 3432885A4
Authority
EP
European Patent Office
Prior art keywords
dextromethorphan
compositions
increasing
methods
pharmacodynamic effects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP17771287.4A
Other languages
German (de)
English (en)
Other versions
EP3432885A1 (fr
Inventor
Herriot TABUTEAU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Antecip Bioventures II LLC
Original Assignee
Antecip Bioventures II LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/130,807 external-priority patent/US9421176B1/en
Priority claimed from US15/164,746 external-priority patent/US9457023B1/en
Priority claimed from US15/164,767 external-priority patent/US9700528B2/en
Priority claimed from US15/182,253 external-priority patent/US9474731B1/en
Priority claimed from US15/206,057 external-priority patent/US9861595B2/en
Priority claimed from US15/213,283 external-priority patent/US20160324807A1/en
Priority claimed from US15/216,545 external-priority patent/US20160339017A1/en
Priority claimed from US15/236,290 external-priority patent/US9763932B2/en
Priority claimed from US15/238,182 external-priority patent/US20160361305A1/en
Priority claimed from US15/275,177 external-priority patent/US20170007558A1/en
Priority claimed from US15/280,938 external-priority patent/US9707191B2/en
Priority to EP24160961.9A priority Critical patent/EP4360628A2/fr
Application filed by Antecip Bioventures II LLC filed Critical Antecip Bioventures II LLC
Publication of EP3432885A1 publication Critical patent/EP3432885A1/fr
Publication of EP3432885A4 publication Critical patent/EP3432885A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP17771287.4A 2016-03-24 2017-03-24 Compositions et méthodes pour augmenter la durée de vie métabolique de dextrométhorphane et effets pharmacodynamiques associés Ceased EP3432885A4 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP24160961.9A EP4360628A2 (fr) 2016-03-24 2017-03-24 Compositions et procédés pour augmenter la durée de vie métabolique du dextrométhorphane et effets pharmacodynamiques associés

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
US201662313067P 2016-03-24 2016-03-24
US201662313620P 2016-03-25 2016-03-25
US201662323438P 2016-04-15 2016-04-15
US15/130,807 US9421176B1 (en) 2013-11-05 2016-04-15 Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US201662336533P 2016-05-13 2016-05-13
US15/164,767 US9700528B2 (en) 2013-11-05 2016-05-25 Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US15/164,746 US9457023B1 (en) 2013-11-05 2016-05-25 Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US15/182,253 US9474731B1 (en) 2013-11-05 2016-06-14 Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US15/206,057 US9861595B2 (en) 2013-11-05 2016-07-08 Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US15/213,283 US20160324807A1 (en) 2013-11-05 2016-07-18 Bupropion as a modulator of drug activity
US15/216,545 US20160339017A1 (en) 2013-11-05 2016-07-21 Bupropion as a modulator of drug activity
US15/224,233 US20160375008A1 (en) 2013-11-05 2016-07-29 Bupropion as a modulator of drug activity
US15/236,290 US9763932B2 (en) 2013-11-05 2016-08-12 Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US15/238,182 US20160361305A1 (en) 2013-11-05 2016-08-16 Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
US15/263,138 US9700553B2 (en) 2013-11-05 2016-09-12 Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US15/275,177 US20170007558A1 (en) 2013-11-05 2016-09-23 Hydroxybupropion and related compounds as modulators of drug plasma levels
US15/280,938 US9707191B2 (en) 2013-11-05 2016-09-29 Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
PCT/US2017/024140 WO2017165845A1 (fr) 2016-03-24 2017-03-24 Compositions et méthodes pour augmenter la durée de vie métabolique de dextrométhorphane et effets pharmacodynamiques associés

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP24160961.9A Division EP4360628A2 (fr) 2016-03-24 2017-03-24 Compositions et procédés pour augmenter la durée de vie métabolique du dextrométhorphane et effets pharmacodynamiques associés

Publications (2)

Publication Number Publication Date
EP3432885A1 EP3432885A1 (fr) 2019-01-30
EP3432885A4 true EP3432885A4 (fr) 2019-11-20

Family

ID=59899814

Family Applications (2)

Application Number Title Priority Date Filing Date
EP24160961.9A Pending EP4360628A2 (fr) 2016-03-24 2017-03-24 Compositions et procédés pour augmenter la durée de vie métabolique du dextrométhorphane et effets pharmacodynamiques associés
EP17771287.4A Ceased EP3432885A4 (fr) 2016-03-24 2017-03-24 Compositions et méthodes pour augmenter la durée de vie métabolique de dextrométhorphane et effets pharmacodynamiques associés

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP24160961.9A Pending EP4360628A2 (fr) 2016-03-24 2017-03-24 Compositions et procédés pour augmenter la durée de vie métabolique du dextrométhorphane et effets pharmacodynamiques associés

Country Status (2)

Country Link
EP (2) EP4360628A2 (fr)
WO (1) WO2017165845A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130274282A1 (en) * 2012-04-16 2013-10-17 Herriot Tabuteau Compositions and methods comprising celecoxib or related compounds and dextromethorphan
SG10201911808QA (en) * 2013-11-05 2020-01-30 Antecip Bioventures Ii Llc Compositions and methods comprising bupropion or related compounds and dextromethorphan
US9402843B2 (en) * 2013-11-05 2016-08-02 Antecip Bioventures Ii Llc Compositions and methods of using threohydroxybupropion for therapeutic purposes
US9198905B2 (en) * 2013-11-05 2015-12-01 Antecip Bioventures Ii Llc Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number Publication date
EP4360628A2 (fr) 2024-05-01
WO2017165845A1 (fr) 2017-09-28
EP3432885A1 (fr) 2019-01-30

Similar Documents

Publication Publication Date Title
EP3534919A4 (fr) Compositions d'organoïdes hépatiques et procédés de préparation et d'utilisation correspondants
EP3302057A4 (fr) Méthodes et compositions d'inhibition de l'interaction de la ménine avec les protéines mll
EP3303317A4 (fr) Méthodes et compositions d'inhibition de l'interaction de la ménine avec les protéines mll
EP3317405A4 (fr) Compositions et procédés pour la reprogrammation de cellules non neuronales en cellules analogues aux neurones
EP3471772A4 (fr) Compositions et méthodes de déplétion de cellules
EP3405577B8 (fr) Compositions et procédés pour inhiber le facteur d
EP3337823A4 (fr) Compositions de support-agent de liaison et leurs procédés de fabrication et d'utilisation
EP3258962A4 (fr) Compositions d'allergènes mélangés et leurs procédés d'utilisation
EP3316909A4 (fr) Anticorps anti-ntb-a ainsi que compositions et procédés associés
EP3065742A4 (fr) Compositions et procédés comprenant du bupropion ou des composés apparentés et du dextrométhorphane
EP3630949A4 (fr) Compositions et procédés d'obtention d'organoïdes
EP3273950A4 (fr) Compositions adjuvantes et méthodes associées
EP3474857A4 (fr) Compositions et méthodes de libération d'agents thérapeutiques
EP3503879A4 (fr) Compositions et procédés associés
EP3436083A4 (fr) Nouvelles compositions et méthodes
EP3532633A4 (fr) Compositions et procédés pour la production de composés
EP3442543A4 (fr) Compositions et méthodes pour la neurogenèse
EP3426349A4 (fr) Procédés et compositions pour inhiber l'expression de pmp22
EP3013364A4 (fr) Compositions contre la tuberculose et méthodes d'utilisation de celles-ci
EP3253403A4 (fr) Procédés et compositions pour améliorer la fonction cognitive
EP3706558A4 (fr) Compositions et procédés d'aquaculture
EP3436467A4 (fr) Nouvelles compositions et méthodes thérapeutiques
EP3094341A4 (fr) Compositions d'énolase 1 (eno1) et leurs utilisations
EP3307284A4 (fr) Compositions et procédés pour l'enrichissement de cellules
EP3532055A4 (fr) Compositions et procédés pour la production de composés

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20181024

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20191023

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 45/06 20060101ALI20191017BHEP

Ipc: A61K 31/137 20060101ALI20191017BHEP

Ipc: A61P 25/28 20060101ALI20191017BHEP

Ipc: A61K 31/485 20060101AFI20191017BHEP

Ipc: A61P 25/24 20060101ALI20191017BHEP

Ipc: A61K 31/55 20060101ALI20191017BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40002749

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20210415

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230414

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20240206